Fragment based drug discovery using fluorescence correlation spectroscopy techniques: Challenges and solutions

Current Topics in Medicinal Chemistry

Volumn 7, Issue 16, 2007, Pages 1582-1591

  Hesterkamp, Thomas ^a   Barker, J ^b   Davenport, A ^b   Whittaker, M ^b  

^a Evotec   (Germany)

^b EVOTEC UK LTD   (United Kingdom)

Author keywords

Biochemical assay; Fragments; Haematopoietic; High concentration; Prostaglandin D2 synthase; Screening; Single molecule spectroscopy; X ray crystallography

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; GELATINASE INHIBITOR; GYRASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; THROMBIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BINDING AFFINITY; BINDING ASSAY; BIOASSAY; BIOPHYSICS; CONCENTRATION RESPONSE; DEVICE; DIFFERENTIAL SCANNING CALORIMETRY; DIFFERENTIAL SCANNING FLUORIMETRY; DIFFERENTIAL STATIC LIGHT SCATTERING; DRUG BINDING; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; EQUILIBRIUM DIALYSIS; FLUORESCENCE CORRELATION SPECTROSCOPY; FLUOROMETRY; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; LIGHT SCATTERING; MEDICAL LITERATURE; MOLECULAR LIBRARY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; LIGANDS; PROTEIN BINDING; PROTEINS; SMALL MOLECULE LIBRARIES; SPECTROMETRY, FLUORESCENCE;

EID: 36348998688     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607782341064     Document Type: Review

References (62)

1. Barker, J.; Courtney, S.; Hesterkamp, T.; Ullmann, D.; Whittaker, M. Fragment screening by biochemical assay. Expert Opin. Drug Discov. 2006, 1, 225-236.
2. Erlanson, D.A.; McDowell, R.S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482.
3. Rees, D.C.; Congreve, M.; Murray, C.W.; Carr, R. Fragment-based lead discovery. Nature Rev. Drug Discov. 2004, 3, 660-672.
4. Fattori, D. Molecular recognition: The fragment approach in lead generation. Drug Discov. Today 2004, 9, 229-238
5. Carr, R.A.; Congreve, M.; Murray, C.W.; Rees, D.C. Fragment-based lead discovery: Leads by design. Drug Discov. Today 2005, 10, 987-992.
6. Zartler, E.R.; Shapiro, M.J. Fragonomics: Fragment-based drug discovery. Curr. Opin. Chem. Biol. 2005, 9, 366-370.
7. McGovern, S.L.; Caselli, C.; Grigorieff, N.; Shoichet, B.K. A common mechanism underlying promiscous inhibitors from virtual and high-throughput screening. J. Med. Chem. 2002, 45, 1712-1722.
8. Seidler, J.; McGovern, S.L.; Doman, T.N.; Shoichet, B.K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 2003, 46, 4477-4486.
9. Hann, M.M.; Leach, A.R.; Harper, G. Molecular Complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
10. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A "Rule of Three" for fragment-based lead discovery. Drug Discov. Today 2003, 8, 876-877.
11. Liebeschuetz, J.W.; Jones, S.D.; Morgan, P.J.; Murray, C.W.; Rimmer, A.D.; Roscoe, J.M.; Waszkowycz, B.; Welsh, P.M.; Wylie, W.A.; Young, S.C.; Martin, H.; Mahler, J.; Brady, L.; Wilkinson, K. PRO SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors. J. Med. Chem. 2002, 45, 1221-1232.
12. Wang, X.; Choe, Y.; Craik, C.S.; Ellman, J.A. Design and synthesis of novel inhibitors of gelatinase B. Bioorg. Med. Chem. Lett. 2002, 12, 2201-2204.
13. Patterson, A.W.; Wood, W.J.; Hornsby, M.; Lesley, S.; Spraggon, G.; Ellman, J.A. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin S using the substrate activity screening method. J. Med. Chem. 2006, 49, 6298-6307.
14. Maly, D.J.; Choong, I.C.; Ellman, J.A. Combinatorial target-guided ligand assembly: Identification of potent subtype-selective e-Src inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 2419-2424.
15. Boehm, H.-J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel inhibitors of DNA gyrase: 3D based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 2000, 43, 2664-2674.
16. Card, G.L.; Blasdel, L.; England, B.P.; Zhang, C.; Suzuki, Y.; Gillette, S.; Fong, D.; Ibrahim, P.N.; Artis, D.R.; Bollag, G.; Milburn, M.V.; Kim, S.H.; Schlessinger, J.; Zhang, K.Y. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat. Biotechnol. 2005, 23, 201-207.
17. Black, E.; Breed, J.; Breeze, A.L.; Embrey, K.; Garcia, R.; Gero, T.W.; Godfrey, L.; Kenny, P.W.; Morley, A.D.; Minshull, C.A.; Pannifer, A.D.; Read, J.; Rees, A.; Russell, D.J.; Toader, D.; Tucker, J. Structure-based design of protein tyrosine phosphatase-1B inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2503-2507.
18. Kehoe, J.W.; Maly, D.J.; Verdugo, D.E.; Armstrong, J.I.; Cook, B.N.; Ouyang, Y.B.; Moore, K.L.; Ellman, J.A.; Bertozzi, C.R. Tyrosylprotein sulfotransferase inhibitors generated by combinatorial target-guided ligand assembly. Bioorg. Med. Chem. Lett. 2002, 12, 329-332.
19. Schilling, S.; Niestrok, A.J.; Rahfeld, J.U.; Hoffmann, T.; Wermann, M.; Zunkel, K.; Wasternack, C.; Demuth, H.U. Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators. J. Biol. Chem. 2003, 278, 49773-49779.
20. Buchholz, M.; Heiser, U.; Schilling, S.; Niestroj, A.J.; Zunkel, K.; Demuth, H.U. The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. J. Med. Chem. 2006, 49, 664-677.
21. He, M.M.; Smith, A.S.; Oslob, J.D.; Flanagan, W.M.; Braisted, A.C., Whitty, A.; Cancilla, M.T.; Wang, J.; Lugovskoy, A.A.; Yoburn, J.C.; Fung, A.D.; Farrington, G.; Eldredge, J.K.; Day, E.S.; Cruz, L.A.; Cachero, T.G.; Miller, S.K.; Friedman, J.E.; Choong, I.C.; Cunningham, B.C. Small-molecule inhibition of TNF-alpha. Science 2005, 310, 1022-1025.
22. Leach, A.R.; Hann, M.M.; Burrows, J.N.; Griffen, E.J. Fragment screening: An introduction. Mol. BioSyst. 2006, 2, 429-446.
23. Armer, R.E.; Cowley, P.M. Trends in Medicinal Chemistry 2004. Drug News Perspect. 2005, 18, 142-148.
24. Kask, P.; Palo, K.; Ullmann, D.; Gall, K. Fluorescence-intensity distribution analysis and its application in biomolecular detection technology. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13756-13761.
25. Eggeling, C.; Brand, I.; Ullmann, V.; Jaeger, S. Highly sensitive fluorescence detection technology currently available for HTS. Drug Discov. Today 2003, 8, 632-641.
26. Benson, N.; Boyd, H.F.; Everett, J.R.; Fries, J.; Gribbon, P.; Haque, N.; Henco, K.; Jessen, T.; Martin, W.H.; Mathewson, T.J.; Sharp, R.E.; Spencer, R.W.; Stuhmeier, F.; Wallace, M.S.; Winkler, D. NanoStore: A concept for logistical improvements of compound handling in high throughput screening. J. Biomol. Screen. 2005, 10, 573-580.
27. Tjernberg, A.; Markova, N.; Griffiths, W.J.; Hallen, D. DMSO-related effects in protein characterization. J. Biomol. Screen. 2006, 11, 131-137.
28. Hajduk, P.J.; Huth, J.R.; Fesik, S.W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 2005, 49, 2518-1525.
29. Huth, J.R.; Sun, C.; Sauer, D.R.; Hajduk, P.J. Utilization of NMR-derived fragment leads in drug design. Methods Enyzmol. 2005, 394, 549-571.
30. Fesik, S.W.; Hajduk, P.J. Use of nuclear magnetic resonance to identify ligands to target biomolecules. 1997. US patent 5,698,401.
31. Pellecchia, M. Solution nuclear magnetic resonance spectroscopy techniques for probing intermolecular interactions. Chem. Biol. 2005, 12, 961-971.
32. Weber, P.C.; Salemme, F.R. Applications of calorimetric methods to drug discovery and the study of protein interactions. Curr. Opin. Struct. Biol. 2003, 13, 115-121.
33. Luque, I.; Freire, E. Structure based prediction of binding affinities and molecular design of peptide ligands. Methods Enzymol. 1998, 295, 100-127.
34. Leavitt, S.; Freire, E. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr. Opin. Struct. Biol. 2001, 11, 560-566.
35. Turnbull, W.B.; Daranas, A.H. One the value of c: Can low affinity systems be studied by isothermal titration calorimetry? J. Am. Chem. Soc. 2003, 125, 14859-14866
36. Wiseman, T.; Williston, S.; Brandts, J.F.; Lin, L.-N. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 1989, 179, 131-137
37. Ciulli, A.; Williams, G.; Smith, A.G.; Blundell, T.L.; Abell, C. Probing hot spots at protein-ligand binding sites: A fragment-based approach using biophysical methods. J. Med. Chem. 2006, 49, 4992-5000.
38. Sigurskjold, B.W. Exact analysis of competition ligand binding by displacement isothermal titration calorimetry. Anal. Biochem. 2000, 277, 260-266.
39. Zhang, Y.-L.; Zhang, Z.-Y. Low-affinity binding determined by titration calorimetry using a high affinity coupling ligand: A thermodynamic study of ligand binding to protein tyrosine phosphatase 1B. Anal. Biochem. 1998, 261, 139-148.
40. Waldron, T.T.; Murphy, K.P. Stabilization of proteins by ligand binding: application to drug screening and determination of unfolding energetics. Biochemistry 2003, 42, 5058-5064.
41. Bruylants, G.; Wouters, J.; Michaux, C. Differential scanning calorimetry in life sciences: Thermodynamics, stability, molecular recognition and application in drug design. Curr. Med. Chem. 2005, 12, 2011-2020.
42. Brands, J.F.; Lin, L.N. Study of strong to ultratight protein interactions using differential scanning calorimetry. Biochemistry 1990, 29, 6927-6940.
43. Weber, P.C.; Pantoliano, M.W.; Simons, D.M.; Salemme, F.R. Structure-based design of synthetic azobenzene ligands for streptavidin. J. Am. Chem. Soc. 1994, 116, 2717-2724.
44. Pantoliano, M.W.; Petrella, E.C.; Kwasnoski, J.D.; Lobanov, V.S.; Myslik, J.; Graf, E.; Carver, T.; Asel, E.; Springer, B.A.; Lane, P.; Salemme, F.R. High density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 2001, 6, 429-440.
45. Bullock, A.N.; Debreczeni, J.E.; Fedorov, O.Y.; Nelson, A.; Marsden, B.D.; Knapp, S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in Moloney murine leukemia virus [PIM-1] kinase. J. Med. Chem. 2005, 48, 7604-7614
46. Matulis, D.; Kranz, J.F.; Salemme, R.R.; Todd, M.J. Thermodynamic stability of carbonic anhydrase: Measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 2005, 44, 5258-5266.
47. Vedadi, M.; Niesen, F.H., Allali-Hassani, A.; Fedorov, O.Y.; Finerty Jr., P.J.; Wasney, G.A.; Yeung, R.; Arrowsmith, C.; Ball, L.J.; Berglund, H.; Hui, R.; Marsden, B.D.; Nordlund, P.; Sundstrom, M.; Weigelt, J.; Edwards, A.M. Chemical screening methods to identify ligands that promote stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 15835-15840.
48. Cummings, M.D.; Farnum, M.A.; Nelen, M.I. Universal screening methods and applications of Thermofluor® J. Biomol. Screen. 2006, 11, 854-863.
49. Pantoliano, M.W.; Rhind, A.W.; Salemme, F.R.; Springer, B.A.; Bone, R.F.; Petrella, E.C. Microplate thermal shift assay and apparatus for ligand development and multi-variable protein chemistry optimization. 1997. International Publication Number WO 97/42500.
50. Lo, M.-C.; Aulabaugh, A.; Jin, G.; Cowling, R.; Bard, J.; Malamas, M.; Ellestad, G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 2004, 332, 153-159.
51. Senisterra, G.A.; Markin, E.; Yamazaki, K.; Hui, R.; Vedadi M.; Awrey, D.E. Screening for ligands using a generic and high-throughput light-scattering-based assay. J. Biomol. Screen. 2006, 11, 940-948.
52. Kurganov, B.I. Kinetics of protein aggregation. Quantitative estimation of the chaperone-like activity in test systems based on suppression of protein aggregation. Biochemistry (Moscow) 2002, 67, 492-507.
53. Senisterra, G.; Hui, R.; Vedadi, M. Methods and apparatuses for characterizing refolding and aggregation of biological molecules. 2005. US Patent Application Publication number US 2005/0079526
54. Papalia, G.A.; Leavitt, S.; Bynum, M.A.; Katsamba, P.S.; Wilton, R.; Qiu, H.; Steukers, M.; Wang, S.; Bindu, L.; Phogat, S.; Gianetti, A.M.; Ryan, T.E.; Pudlak, V.A.; Matusiewicz, K.; Michelson, K.M.; Nowakowski, A.; Pham-Baginski, A.; Brooks, J.; Tieman, B.C.; Bruce, B.D.; Vaughn, M.; Baksh, M.; Cho, Y.H.; De Wit, M.; Smets, A.; Vandersmissen, J.; Michiels, L.; Myszka, D.G. Comparative analysis of 10 small molecules binding to carbonic anhydrase II by different investigators using Biacore technology. Anal. Biochem. 2006, 359, 94-105.
55. Pattnaik, P Surface plasmon resonance. Appl. Biochem. Biotechnol., 2005, 126, 79-92.
56. Huber, W.; Mueller, F. Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology. Curr. Pharm. Des. 2006, 12, 3999-4021.
57. Wan, H.; Rehngren, M. High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry. J. Chromatogr. A 2006, 1102, 125-134.
58. Matsuoki, T.; Hirata, M.; Tanaka, H.; Takahashi, Y.; Murata, I.; Kabashima, K.; Sugimoto, Y.; Kobayashi, T.; Ushikubi, F.; Aze, Y.; Eguchi, N.; Urade, Y.; Yoshida, N.; Kimura, K.. Mizoguchi, A.; Honda, Y.; Nagai, H.; Narumiya, S. Prostaglandin D2 as a mediator of allergic asthma. Science, 2000, 287, 2013-2017.
59. Hirai, H.; Tanaka, K.; Yoshie, O.; Ogawa, K.; Kenmotsu, K.; Takamori, Y.; Ichimasa, M.; Sugamura, K.; Nakamura, M.; Takano, S.; and Nagata K. Prostaglandin D2 selectively induces chemotaxisin T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Med. 2001, 193, 255-262.
60. Quinkler, M.; Bujalska, I.J.; Tomlinson, J.W.; Smith, D.M.; Stewart, P.M. Depot-specific prostaglandin synthesis in human adipose tissue: A novel possible mechanism of adipogenesis. Gene 2006, 380, 137-143.
61. Okano, M.; Fujiwara, T.; Yamamoto, M.; Sugata, Y.; Matsumoto, R.; Fukushima, K.; Yoshino, T.; Shimizu, K.; Eguchi, N.; Kiniwa, M.; Urade, Y.; Nishizaki, K. Role of prostaglandin D2 and E2 terminal synthases in chronic rhinosinusitis. Clin. Exper. Allergy 2006, 36, 1028-1038.
62. Trivedi, S.G.; Newson, J.; Rajakariar, R.; Jacques, T.S.; Hannon, R.; Kanaoka, Y.; Eguchi, N.; Colville-Nash, P.; Gilroy, D.W. Essential role for haematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13, 5179-5184.